UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

Frontiers in pharmacology, 2018-11, Vol.9, p.1365-1365

2018

Volltextzugriff (PDF)

A Novel Transwell Blood Brain Barrier Model Using Primary Human Cells

Frontiers in cellular neuroscience, 2019-06, Vol.13, p.230-230

2019

Volltextzugriff (PDF)

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

The Lancet (British edition), 2011-01, Vol.377 (9763), p.393-402

2011

Volltextzugriff (PDF)

Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

The New England journal of medicine, 2007-11, Vol.357 (22), p.2237-2247

2007

Volltextzugriff (PDF)

Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial

Nature communications, 2024-06, Vol.15 (1), p.4690-14

2024

Volltextzugriff (PDF)

An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers

Frontiers in behavioral neuroscience, 2018-11, Vol.12, p.269-269

2018

Volltextzugriff (PDF)

A systematic review of minor phytocannabinoids with promising neuroprotective potential

British journal of pharmacology, 2020-10, Vol.177 (19), p.4330-4352

2020

Volltextzugriff (PDF)

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

The New England journal of medicine, 2023-11, Vol.389 (21), p.1961-1971

2023

Volltextzugriff (PDF)

Apoptotic Membrane Blebbing Is Regulated by Myosin Light Chain Phosphorylation

The Journal of cell biology, 1998-02, Vol.140 (3), p.627-636

1998

Volltextzugriff (PDF)

Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

British journal of haematology, 2013-02, Vol.160 (4), p.538-546

2013

Volltextzugriff (PDF)

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions

Cannabis and cannabinoid research, 2021-08, Vol.6 (4), p.315-326

2021

Volltextzugriff (PDF)

Rho kinase regulates fragmentation and phagocytosis of apoptotic cells

Experimental cell research, 2006, Vol.312 (1), p.5-15

2006

Volltextzugriff (PDF)

Extranuclear Apoptosis: The Role of the Cytoplasm in the Execution Phase

The Journal of cell biology, 1999-08, Vol.146 (4), p.703-707

1999

Volltextzugriff (PDF)

Generalizable FGFR prediction across tumor types using self supervised learning

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15057-e15057

2023

Volltextzugriff (PDF)

FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4578-4578

2024

Volltextzugriff (PDF)

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS583-TPS583

2023

Volltextzugriff (PDF)

PD48-02 FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.676-676

2024

Volltextzugriff (PDF)

Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes -based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16509-e16509

2019

Volltextzugriff (PDF)

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9093-9093

2019

Volltextzugriff (PDF)

Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura

Blood, 2009-11, Vol.114 (22), p.3517-3517

2009

Volltextzugriff (PDF)

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura

Blood, 2008-11, Vol.112 (11), p.3431-3431

2008

Volltextzugriff (PDF)

1 – 25 von 215

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(179)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

A Novel Transwell Blood Brain Barrier Model Using Primary Human Cells

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial

An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers

A systematic review of minor phytocannabinoids with promising neuroprotective potential

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

Apoptotic Membrane Blebbing Is Regulated by Myosin Light Chain Phosphorylation

Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions

Rho kinase regulates fragmentation and phagocytosis of apoptotic cells

Extranuclear Apoptosis: The Role of the Cytoplasm in the Execution Phase

Generalizable FGFR prediction across tumor types using self supervised learning

FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro)

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study

PD48-02 FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS

Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210

Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes -based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC)

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy

Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura

Suchergebnisse filtern